Beacon Financial Group grew its position in McKesson Co. (NYSE:MCK) by 7.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,911 shares of the company’s stock after purchasing an additional 596 shares during the period. Beacon Financial Group’s holdings in McKesson were worth $1,043,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Proficio Capital Partners LLC raised its holdings in McKesson by 161.2% in the fourth quarter. Proficio Capital Partners LLC now owns 222 shares of the company’s stock worth $25,000 after purchasing an additional 137 shares during the period. Bedel Financial Consulting Inc. raised its holdings in McKesson by 165.2% in the fourth quarter. Bedel Financial Consulting Inc. now owns 236 shares of the company’s stock worth $26,000 after purchasing an additional 147 shares during the period. Dubuque Bank & Trust Co. raised its holdings in McKesson by 106.7% in the first quarter. Dubuque Bank & Trust Co. now owns 341 shares of the company’s stock worth $40,000 after purchasing an additional 176 shares during the period. Old North State Trust LLC raised its holdings in McKesson by 53.3% in the fourth quarter. Old North State Trust LLC now owns 391 shares of the company’s stock worth $43,000 after purchasing an additional 136 shares during the period. Finally, IMS Capital Management acquired a new stake in McKesson in the third quarter worth $57,000. Institutional investors own 86.60% of the company’s stock.
MCK has been the topic of several analyst reports. ValuEngine lowered shares of McKesson from a “sell” rating to a “strong sell” rating in a report on Friday, March 1st. UBS Group initiated coverage on shares of McKesson in a report on Thursday, January 17th. They set a “neutral” rating and a $134.00 price objective on the stock. Zacks Investment Research lowered shares of McKesson from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. Deutsche Bank upgraded shares of McKesson from a “sell” rating to a “hold” rating and set a $175.00 price objective on the stock in a report on Friday, January 25th. Finally, Barclays restated a “hold” rating and set a $124.00 price objective on shares of McKesson in a report on Sunday, January 6th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $134.90.
Shares of NYSE:MCK traded up $0.78 during midday trading on Thursday, reaching $113.27. 20,987 shares of the company were exchanged, compared to its average volume of 1,555,124. McKesson Co. has a fifty-two week low of $106.11 and a fifty-two week high of $160.84. The company has a quick ratio of 0.57, a current ratio of 1.02 and a debt-to-equity ratio of 0.81. The firm has a market cap of $21.58 billion, a price-to-earnings ratio of 8.97, a PEG ratio of 1.19 and a beta of 1.24.
McKesson (NYSE:MCK) last released its earnings results on Thursday, January 31st. The company reported $3.40 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.22. The business had revenue of $56.21 billion during the quarter, compared to the consensus estimate of $55.27 billion. McKesson had a negative net margin of 0.15% and a positive return on equity of 27.83%. During the same quarter last year, the firm earned $3.41 earnings per share. Research analysts expect that McKesson Co. will post 13.55 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Monday, April 1st. Investors of record on Friday, March 1st were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 1.38%. The ex-dividend date of this dividend was Thursday, February 28th. McKesson’s dividend payout ratio (DPR) is currently 12.36%.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Recommended Story: Quick Ratio
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.